All‐cause mortality · prevention and treatment of hepatic encephalopathy in people with cirrhosis
Non‐absorbable disaccharides probably leads to lower mortality compared with placebo/no intervention (moderate certainty).
1 finding from 1 review
Hepatic encephalopathy · prevention and treatment of hepatic encephalopathy in people with cirrhosis
Non‐absorbable disaccharides probably leads to lower hepatic encephalopathy compared with placebo/no intervention (moderate certainty).
1 finding from 1 review
Serious adverse events · prevention and treatment of hepatic encephalopathy in people with cirrhosis
Non‐absorbable disaccharides probably leads to lower serious adverse events compared with placebo/no intervention (moderate certainty).
1 finding from 1 review
Secondary outcome: quality of life · prevention and treatment of hepatic encephalopathy in people with cirrhosis
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Non‐serious adverse events (secondary outcome) · prevention and treatment of hepatic encephalopathy in people with cirrhosis
It is very uncertain whether non‐absorbable disaccharides changes non‐serious adverse events (secondary outcome) compared with placebo/no intervention (very low certainty).
1 finding from 1 review
Mortality ‐ total number · prevention and treatment of hepatic encephalopathy in people with cirrhosis
Summary of findings table ‐ Rifaximin plus non‐absorbable… probably leads to lower mortality ‐ total number compared with non‐absorbable disaccharides alone (moderate certainty).
1 finding from 1 review
Serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis
It is very uncertain whether summary of findings table ‐ Rifaximin plus non‐absorbable… changes serious adverse events ‐ total number of participants compared with non‐absorbable disaccharides alone (very low certainty).
1 finding from 1 review
Hepatic encephalopathy · prevention and treatment of hepatic encephalopathy in people with cirrhosis
Summary of findings table ‐ Rifaximin plus non‐absorbable… may leads to lower hepatic encephalopathy ‐ total number compared with non‐absorbable disaccharides alone (low certainty).
1 finding from 1 review
Non‐serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis
It is very uncertain whether summary of findings table ‐ Rifaximin plus non‐absorbable… changes non‐serious adverse events ‐ total number of participants compared with non‐absorbable disaccharides alone (very low certainty).
1 finding from 1 review
Blood ammonia measured in μg/mL at trial end · prevention and treatment of hepatic encephalopathy in people with cirrhosis
1 finding from 1 review
Number Connection Test A, assessed using: seconds (1 trial) or Z‐score (1 trial) at trial end · prevention and treatment of hepatic encephalopathy in people with cirrhosis
1 finding from 1 review
All‐cause mortality · adults with cirrhosis and hepatic encephalopathy
1 finding from 1 review
Blood ammonia concentrations (units unspecified) · adults with cirrhosis and hepatic encephalopathy
3 findings from 1 review
no estimate extracted
1 study · 35 participants
Very low
no estimate extracted
1 study · 16 participants
Very low
no estimate extracted
1 study · 231 participants
Very low
Blood ammonia concentrations (µmol/L*week) · adults with cirrhosis and hepatic encephalopathy
2 findings from 1 review
Hepatic encephalopathy · adults with cirrhosis and hepatic encephalopathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults with cirrhosis and hepatic encephalopathy
1 finding from 1 review
Non‐serious adverse events · adults with cirrhosis and hepatic encephalopathy
1 finding from 1 review
Health‐related quality of life · adults with cirrhosis and hepatic encephalopathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Plasma ammonia concentration (µmol/L) · adults with cirrhosis and hepatic encephalopathy
1 finding from 1 review
Non‐serious adverse events (secondary outcome) · prevention and treatment of hepatic encephalopathy in people with cirrhosis
It is very uncertain whether lactulose changes non‐serious adverse events (secondary outcome) compared with lactitol (very low certainty).
1 finding from 1 review